The Archive · 32,142 records

Source documents — page 33 of 129

Source documents, page 33 of 129: records 8,001–8,250 of 32,142, titles C.

Browse by source, program, docket, document type or year.

Records 8,001–8,250 of 32,142

C

Crossroads Systems, Inc. Announces Merger With Rise Line Business Credit (PR Newswire)Archived source document: Crossroads Systems, Inc. Announces Merger With Rise Line…
Crossroads Systems, Inc., Schedule 13D, 210/CRDS Investment LLC (Oct. 24, 2017)Archived source document: Crossroads Systems, Inc., Schedule 13D, 210/CRDS Investment LLC…
Crossroads team page, Eric Donnelly bio SMU economics; hired 2012, CEO 2014; 2005 small-balance CRE finance company;...Crossroads Impact Corp team page biography of Eric Donnelly, CEO and former Capital Plus…
Crow Hosts Forum Examining the Issues Facing Small Business Insurance Policyholders Related to COVID-19House Small Business subcommittee release, May 21, 2020: Chairman Jason Crow's virtual…
Crow Looks to Clean Energy Economy to Boost Small Business Job GrowthRelease of July 27, 2021, on a Crow-chaired subcommittee hearing on the clean energy…
Crow Looks to Ease Workforce Issues in the Aviation and Aerospace IndustryMay 12, 2022 release on a House Small Business subcommittee hearing on workforce issues…
Crow Looks to Ease Workforce Issues in the Aviation and Aerospace Industry (May 12, 2022)Statement, May 12, 2022, on a House Small Business subcommittee hearing led by Chairman…
Crow Looks to Improve SBA Technology Systems Hindering COVID-19 Relief ProgramsCmte Small Business (D) release on a subcommittee hearing about SBA technology systems…
Crow Looks to Strengthen Innovation Between Universities and Small BusinessesRelease on a House Small Business subcommittee hearing on collaboration between research…
Crow Looks to Utilize SBA Resource Partners to Drive Small Business Recovery (May 19, 2021)Announcement of a House Small Business subcommittee hearing on SBA resource partners,…
Crow Pushes to Increase Entrepreneurship to Drive Economic RecoveryChairman Jason Crow's June 30, 2021 release on a hearing about declining entrepreneurship…
Crow Seeks to Utilize Workforce Development to Train Next Generation of Infrastructure WorkersMay 6, 2021 House Small Business subcommittee release on workforce development to train…
Crow Surveys Role of Small Business in Ag-Tech and Impact of New Technologies on Small FarmsPress release, January 9, 2020: Rep. Jason Crow's subcommittee examines small business,…
Crow Touts Workforce Development as Tool to Ease Labor ShortagesSmall Business Committee release of March 31, 2022, on a hearing about workforce…
Crunchbase News, "Wholesale Marketplace Faire Secures $100M At $535M Valuation"Crunchbase News, "Wholesale Marketplace Faire Secures $100M At $535M Valuation".
Crunchbase, Noah Spirakus profile career: Bold Financial Technologies → Airbnb; Prospectify → AngelList; TechstarsCrunchbase profile of Noah Spirakus: Head of Engineering at AngelList, with 4 past jobs…
Crushing the Virus (Cong. Rec., March 11, 2021)Congressional Record, House, March 11, 2021 (H1330): one-minute speeches on the American…
CSDE ARP ESSER State Plan, Grantee InformationCover of a CSDE ARP ESSER State Plan, award S425U210030, signed by Charlene M.…
CSTE Interim position statement 20-ID-01 (COVID-19 case definition)CSTE position statement Interim-20-ID-01 setting a standardized COVID-19 surveillance…
CT 16335 - La SBA ofrece asistencia en caso de desastre a las pequeñas empresas de Connecticut afectadas económicamente por el Coronavirus (COVID-19)SBA disaster release CT 16335 (en español), March 16, 2020: COVID-19 working-capital…
CT 16335 - SBA Offers Disaster Assistance to Connecticut Small Businesses Economically Impacted by the Coronavirus (COVID-19)SBA disaster release CT 16335, March 16, 2020: COVID-19 working-capital disaster loans…
CTN - CMX 250507 1339 - Working 1357.xlsxCTN - CMX 250507 1339 - Working 1357.xlsx: court filing dated May 8, 2025. Full text and citation…
Cue Health Announces Pricing of Initial Public OfferingCue Health press release of Sept. 23, 2021: IPO of 12,500,000 shares priced at $16.00 per…
Cue Health Inc. Form 10-K (Dec. 31, 2021)Cue Health Inc. Form 10-K for fiscal year 2021: cover data, business overview and March…
Cue Health Inc. Form 10-K (Dec. 31, 2022)Cue Health Inc. Form 10-K for fiscal year 2022: cover data, Cue Integrated Care Platform…
Cue Health Inc. Form 10-Q (June 30, 2022)Cue Health Inc. Form 10-Q for the quarter ended June 30, 2022: revenue $87,700 thousand,…
Cue Health Inc. Form 10-Q (June 30, 2023)Cue Health Inc. Form 10-Q for the quarter ended June 30, 2023: revenue $9,896 thousand,…
Cue Health Inc. Form 10-Q (March 31, 2022)Cue Health Inc. Form 10-Q for the quarter ended March 31, 2022: revenue $179,410…
Cue Health Inc. Form 10-Q (March 31, 2023)Cue Health Inc. Form 10-Q for the quarter ended March 31, 2023: revenue $24,765 thousand,…
Cue Health Inc. Form 10-Q (Sept. 30, 2021)Cue Health Inc. Form 10-Q for the quarter ended September 30, 2021: revenue $223,679…
Cue Health Inc. Form 10-Q (Sept. 30, 2022)Cue Health Inc. Form 10-Q for the quarter ended September 30, 2022: revenue $69,589…
Cue Health Inc. Form 10-Q (Sept. 30, 2023)Cue Health Inc. Form 10-Q for the quarter ended September 30, 2023: revenue $17,477…
Cue Health Inc. Form 4 — Achar Christopher K (Dec. 5, 2022)Form 4 for Cue Health Inc. director Chris Achar: 4,327 shares withheld on 12/05/2022;…
Cue Health Inc. Form 4 — Achar Christopher K (June 5, 2023)Form 4 for Cue Health Inc. director Chris Achar: 6,965 shares withheld at $0.6 on…
Cue Health Inc. Form 4 — Achar Christopher K (March 2, 2023)Form 4 for Cue Health Inc. director Chris Achar: 85,106 units and a 170,213-share option…
Cue Health Inc. Form 4 — Achar Christopher K (Sept. 26, 2022)Form 4 for Cue Health Inc. director Chris Achar: 134,629 shares withheld on 09/26/2022;…
Cue Health Inc. Form 4 — Achar Christopher K (Sept. 5, 2023)Form 4 for Cue Health Inc. director Chris Achar: 7,465 shares withheld at $0.51 on…
Cue Health Inc. Form 4 — Bradford K Joanne (June 5, 2023)Form 4 for Cue Health Inc. director Joanne Bradford: 63,300 restricted stock units…
Cue Health Inc. Form 4 — Faig Carole T (June 5, 2023)Form 4 for Cue Health Inc. director Carole Faig: grant of 63,300 restricted stock units…
Cue Health Inc. Form 4 — Gallagher John E (Dec. 28, 2022)Form 4 for Cue Health Inc. Chief Financial Officer John Gallagher: 12,415 shares withheld…
Cue Health Inc. Form 4 — Gallagher John E (Dec. 5, 2022)Form 4 for Cue Health Inc. Chief Financial Officer John Gallagher: 5,334 shares withheld…
Cue Health Inc. Form 4 — Gallagher John E (March 6, 2023)Form 4 for Cue Health Inc. Chief Financial Officer John Gallagher: 6,117 shares withheld…
Cue Health Inc. Form 4 — Gallagher John E (Sept. 28, 2022)Form 4 for Cue Health Inc. Chief Financial Officer John Gallagher: 12,416 shares withheld…
Cue Health Inc. Form 4 — Ghaim Joshua (June 5, 2023)Form 4 for Cue Health Inc. director Joshua Ghaim: 63,300 restricted stock units granted…
Cue Health Inc. Form 4 — Jain Sachin H. (June 5, 2023)Form 4 for Cue Health Inc. director Sachin Jain: 63,300 restricted stock units granted…
Cue Health Inc. Form 4 — Jain Sachin H. (Oct. 7, 2022)Form 4 for Cue Health Inc. director Sachin Jain: 90,361 restricted stock units granted on…
Cue Health Inc. Form 4 — Javed Aasim (June 5, 2023)Form 4 for Cue Health Inc. Chief Financial Officer Aasim Javed: 11,626 shares withheld at…
Cue Health Inc. Form 4 — Javed Aasim (Sept. 5, 2023)Form 4 for Cue Health Inc. Chief Financial Officer Aasim Javed: 11,623 shares withheld at…
Cue Health Inc. Form 4 — Khattak Ayub K (Dec. 27, 2022)Form 4 for Ayub Khattak, a Cue Health Inc. director and President: 30,248 shares withheld…
Cue Health Inc. Form 4 — Khattak Ayub K (Dec. 5, 2022)Form 4 for Ayub Khattak, a Cue Health Inc. director and President: 12,996 shares withheld…
Cue Health Inc. Form 4 — Khattak Ayub K (June 26, 2023)Form 4 for Ayub Khattak, a Cue Health Inc. director and President: 21,097 shares withheld…
Cue Health Inc. Form 4 — Khattak Ayub K (June 5, 2023)Form 4 for Ayub Khattak, a Cue Health Inc. director and President: 9,064 shares withheld…
Cue Health Inc. Form 4 — Khattak Ayub K (March 2, 2023)Form 4 for Ayub Khattak, a Cue Health Inc. director and President: option for 808,511…
Cue Health Inc. Form 4 — Khattak Ayub K (March 24, 2023)Form 4 for Ayub Khattak, a Cue Health Inc. director and President: 21,028 shares withheld…
Cue Health Inc. Form 4 — Khattak Ayub K (Sept. 26, 2022)Form 4 for Ayub Khattak, a Cue Health Inc. director and President: 30,775 shares withheld…
Cue Health Inc. Form 4 — Khattak Ayub K (Sept. 5, 2023)Form 4 for Ayub Khattak, a Cue Health Inc. director and President: 9,064 shares withheld…
Cue Health Inc. Form 4 — Martinez Maria (June 5, 2023)Form 4 for Cue Health Inc. director Maria Martinez: 63,300 restricted stock units awarded…
Cue Health Inc. Form 4 — Palsis Erica (Dec. 5, 2022)Form 4 for Cue Health Inc. General Counsel Erica Palsis: 5,948 shares withheld for taxes…
Cue Health Inc. Form 4 — Palsis Erica (Feb. 1, 2023)Form 4 for Cue Health Inc. General Counsel Erica Palsis: 39,070 shares withheld at $2.62…
Cue Health Inc. Form 4 — Palsis Erica (June 5, 2023)Form 4 for Cue Health Inc. General Counsel Erica Palsis: 80,000 units granted and 6,272…
Cue Health Inc. Form 4 — Palsis Erica (March 2, 2023)Form 4 for Cue Health Inc. General Counsel Erica Palsis: 127,660 units and a…
Cue Health Inc. Form 4 — Palsis Erica (Sept. 5, 2023)Form 4 for Cue Health Inc. General Counsel Erica Palsis: 6,272 shares withheld at $0.51…
Cue Health Inc. Form 4 — Pollard Randall E. (June 5, 2023)Form 4 for Cue Health Inc. Chief Accounting Officer Randall Pollard: 14,851 shares…
Cue Health Inc. Form 4 — Pollard Randall E. (March 2, 2023)Form 4 for Cue Health Inc. Chief Accounting Officer Randall Pollard: 180,000 restricted…
Cue Health Inc. Form 4 — Pollard Randall E. (Sept. 5, 2023)Form 4 for Cue Health Inc. Chief Accounting Officer Randall Pollard: 6,186 shares…
Cue Health Inc. Form 4 — Sever Clint (Dec. 27, 2022)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: 24,748 shares withheld at…
Cue Health Inc. Form 4 — Sever Clint (Dec. 5, 2022)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: tax withholding on…
Cue Health Inc. Form 4 — Sever Clint (Dec. 8, 2022)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: last 29,269 option shares…
Cue Health Inc. Form 4 — Sever Clint (June 26, 2023)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: 25,782 shares withheld at…
Cue Health Inc. Form 4 — Sever Clint (June 5, 2023)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: 15,885 shares withheld at…
Cue Health Inc. Form 4 — Sever Clint (March 2, 2023)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: 148,936 units and a…
Cue Health Inc. Form 4 — Sever Clint (March 24, 2023)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: 17,115 shares withheld at…
Cue Health Inc. Form 4 — Sever Clint (Nov. 22, 2022)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: 19,089 option shares…
Cue Health Inc. Form 4 — Sever Clint (Nov. 30, 2022)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: 22,725 option shares…
Cue Health Inc. Form 4 — Sever Clint (Nov. 8, 2022)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: plan sales of 26,664 option…
Cue Health Inc. Form 4 — Sever Clint (Oct. 11, 2022)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: 26,664 option shares…
Cue Health Inc. Form 4 — Sever Clint (Oct. 25, 2022)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: option exercises and sales…
Cue Health Inc. Form 4 — Sever Clint (Sept. 26, 2022)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: 25,275 shares withheld at…
Cue Health Inc. Form 4 — Sever Clint (Sept. 27, 2022)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: option exercises and sales…
Cue Health Inc. Form 4 — Sever Clint (Sept. 30, 2022)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: 7,374 option shares…
Cue Health Inc. Form 4 — Sever Clint (Sept. 5, 2023)Form 4 for Cue Health Inc. Chief Product Officer Clint Sever: 15,885 shares withheld at…
CUE HEALTH INC. Form 8-K (April 28, 2023)Cue Health Inc. Form 8-K (April 28, 2023): Item 2.05 cost reduction plan cutting 326…
CUE HEALTH INC. Form 8-K (Aug. 10, 2022)Cue Health Inc. Form 8-K (Aug. 10, 2022): Item 2.02 report that a press release on…
CUE HEALTH INC. Form 8-K (Aug. 3, 2023)Cue Health Inc. Form 8-K (Aug. 3, 2023): Item 7.01 report of an approximately $28 million…
CUE HEALTH INC. Form 8-K (Aug. 9, 2023) — Item 1.01Cue Health Inc. Form 8-K (Aug. 9, 2023): Item 1.01 sales agreement with Cowen and…
CUE HEALTH INC. Form 8-K (Aug. 9, 2023) — Item 2.02Cue Health Inc. Form 8-K (Aug. 9, 2023): Item 2.02 report that a press release on…
CUE HEALTH INC. Form 8-K (Feb. 27, 2023)Cue Health Inc. Form 8-K (Feb. 27, 2023): Item 5.02 Chief Financial Officer resignation;…
CUE HEALTH INC. Form 8-K (Jan. 11, 2022)Cue Health Inc. Form 8-K: preliminary fourth quarter and 2021 results and a J.P. Morgan…
CUE HEALTH INC. Form 8-K (Jan. 5, 2023)Cue Health Inc. Form 8-K (Jan. 5, 2023): Item 2.05 cost reduction plan cutting 388…
CUE HEALTH INC. Form 8-K (July 19, 2022)Cue Health Inc. Form 8-K (July 19, 2022): appointment of Dr. Josh Ghaim to the Board, two…
CUE HEALTH INC. Form 8-K (July 9, 2022)Cue Health Inc. Form 8-K: annual meeting set for September 21, 2022, with a July 22, 2022…
CUE HEALTH INC. Form 8-K (June 6, 2023) — Item 3.01Cue Health Inc. Form 8-K (June 6, 2023): Item 3.01 Nasdaq notice under Listing Rule…
CUE HEALTH INC. Form 8-K (June 6, 2023) — Item 7.01Cue Health Inc. Form 8-K (June 6, 2023): Item 7.01 report of FDA De Novo authorization…
CUE HEALTH INC. Form 8-K (March 10, 2023)Cue Health Inc. Form 8-K (March 10, 2023): Item 7.01 statement that it holds no deposits…
CUE HEALTH INC. Form 8-K (March 15, 2023)Cue Health Inc. Form 8-K (March 15, 2023): Item 2.02 report that a press release on…
CUE HEALTH INC. Form 8-K (March 17, 2023)Cue Health Inc. Form 8-K (March 17, 2023): Items 7.01 and 8.01 report an FDA emergency…
CUE HEALTH INC. Form 8-K (March 29, 2022)Cue Health Inc. Form 8-K: press release on fourth quarter and full year ended December…
CUE HEALTH INC. Form 8-K (May 10, 2023)Cue Health Inc. Form 8-K (May 10, 2023): Item 2.02 report that a press release on…
CUE HEALTH INC. Form 8-K (May 11, 2022)Cue Health Inc. Form 8-K: press release on first quarter results for the quarter ended…
CUE HEALTH INC. Form 8-K (Nov. 10, 2021)Cue Health Inc. Form 8-K: third quarter 2021 results press release and…
CUE HEALTH INC. Form 8-K (Nov. 3, 2022)Cue Health Inc. Form 8-K (Nov. 3, 2022): Item 5.03 report that the Board adopted amended…
CUE HEALTH INC. Form 8-K (Nov. 8, 2023)Cue Health Inc. Form 8-K (Nov. 8, 2023): Item 2.02 report that a press release on…
CUE HEALTH INC. Form 8-K (Nov. 9, 2022)Cue Health Inc. Form 8-K (Nov. 9, 2022): Item 2.02 report that a press release on…
CUE HEALTH INC. Form 8-K (Oct. 7, 2022)Cue Health Inc. Form 8-K (Oct. 7, 2022): appointment of Sachin H. Jain, M.D. to the…
CUE HEALTH INC. Form 8-K (Sept. 21, 2022)Cue Health Inc. Form 8-K (Sept. 21, 2022): Item 5.07 report of the annual meeting vote…
CUE HEALTH INC. Form 8-K (Sept. 21, 2023)Cue Health Inc. Form 8-K (Sept. 21, 2023): Item 1.01 Preferred Stock Rights Agreement,…
Cue Health Inc. Form 8-K (Sept. 28, 2021)Cue Health Inc. Form 8-K: restated certificate of incorporation and amended bylaws take…
CUE HEALTH INC. Form S-1/A (Sept. 20, 2021)Cue Health Inc. Amendment No. 2 to Form S-1, No. 333-259250 (Sept. 20, 2021):…
Cue Health Raises $200 Million in IPO At $2.3 Billion Valuation (September 28, 2021)Cue Health raised $200 million in its IPO at a $2.3 billion valuation, per a September…
Culture Meets Crypto: What is PARTI?Promotional handout on PARTI, a live streaming platform with built-in crypto incentives,…
Culver City Restauranteur Pleads Guilty to Fraudulently Obtaining More Than $4 Million in COVID-19 LoansPhilip Frederick Camino pleads guilty to wire fraud conspiracy over more than $4 million…
Curative-Korva SARS-Cov-2 Assay, Emergency Use Authorization (April 16, 2020)Archived source document: Curative-Korva SARS-Cov-2 Assay, Emergency Use Authorization…
Curcio Hearing Transcript, Doc. 54 — U.S. v. MartinezCurcio Hearing Transcript, Doc. 54 — U.S. v. Martinez: court transcript. Full text and citation…
CureVac B.V. Form 424B4 (Aug. 13, 2020)CureVac B.V. prospectus (Rule 424(b)(4), No. 333-240076), Aug. 13, 2020: 13,333,333…
CureVac B.V. Form F-1 (July 24, 2020)CureVac B.V. Form F-1 (SEC, July 24, 2020): initial public offering of common shares,…
CureVac N.V. Form 20-F (Dec. 31, 2020)CureVac N.V. Form 20-F for fiscal year ended Dec. 31, 2020: 180,460,565 shares…
CureVac N.V. Form 20-F (Dec. 31, 2021)CureVac N.V. Form 20-F for fiscal year ended Dec. 31, 2021: 187,120,718 shares…
CureVac N.V. Form 424B4 (Jan. 27, 2021)CureVac N.V. Rule 424(b)(4) prospectus dated January 27, 2021 for 5,000,000 common shares…
CureVac N.V. Form 6-K (April 15, 2021)CureVac N.V. Form 6-K (April 15, 2021), File No. 001-39446: press release on…
CureVac N.V. Form 6-K (April 19, 2021)CureVac N.V. Form 6-K (April 19, 2021), File No. 001-39446: press release on a rolling…
CureVac N.V. Form 6-K (Dec. 14, 2020)CureVac N.V. Form 6-K, December 14, 2020: press release on start of the global pivotal…
CureVac N.V. Form 6-K (Dec. 21, 2020)CureVac N.V. Form 6-K, December 21, 2020: press release on Phase 3 trial of CVnCoV in…
CureVac N.V. Form 6-K (Dec. 4, 2020)CureVac N.V. Form 6-K, December 4, 2020: press release on appointment of Antony Blanc as…
CureVac N.V. Form 6-K (Dec. 9, 2020)CureVac N.V. Form 6-K, December 9, 2020: press release on Fareva fill & finish agreement…
CureVac N.V. Form 6-K (Feb. 1, 2021)CureVac N.V. Form 6-K, February 1, 2021: press release on Rentschler Biopharma support…
CureVac N.V. Form 6-K (Feb. 12, 2021)CureVac N.V. Form 6-K (Feb. 12, 2021), File No. 001-39446: press release on a rolling…
CureVac N.V. Form 6-K (Feb. 2, 2021)CureVac N.V. Form 6-K dated February 2, 2021: Exhibit 99.1 press release on the closing…
CureVac N.V. Form 6-K (Feb. 3, 2021)CureVac N.V. Form 6-K, February 3, 2021: press release on new collaboration agreement…
CureVac N.V. Form 6-K (Feb. 4, 2021) — Common SharesCureVac N.V. Form 6-K dated February 4, 2021: Exhibit 99.1 press release on the full…
CureVac N.V. Form 6-K (Feb. 4, 2021) — CV8102CureVac N.V. Form 6-K, February 4, 2021: press release on expanded Phase 1 study of its…
CureVac N.V. Form 6-K (Feb. 5, 2021)CureVac N.V. Form 6-K, February 5, 2021: press release on collaboration with the United…
CureVac N.V. Form 6-K (Jan. 11, 2021)CureVac N.V. Form 6-K, January 11, 2021: press release on preclinical data for CVnCoV in…
CureVac N.V. Form 6-K (Jan. 19, 2021)CureVac N.V. Form 6-K, January 2021: EU advance purchase agreement of November 30, 2020…
CureVac N.V. Form 6-K (Jan. 25, 2021)CureVac N.V. Form 6-K dated January 25, 2021: Exhibit 99.1 press release on the proposed…
CureVac N.V. Form 6-K (Jan. 28, 2021)CureVac N.V. Form 6-K dated January 28, 2021: Exhibit 99.1 press release on the pricing…
CureVac N.V. Form 6-K (Jan. 7, 2021)CureVac N.V. Form 6-K, January 7, 2021: press release on collaboration and services…
CureVac N.V. Form 6-K (June 16, 2021)CureVac N.V. Form 6-K (June 16, 2021), File No. 001-39446: press release on second…
CureVac N.V. Form 6-K (June 2, 2021)CureVac N.V. Form 6-K (June 2, 2021), File No. 001-39446: press release announcing Klaus…
CureVac N.V. Form 6-K (June 4, 2021)CureVac N.V. Form 6-K (June 4, 2021), File No. 001-39446: convening of the June 24, 2021…
CureVac N.V. Form 6-K (March 22, 2021)CureVac N.V. Form 6-K (March 22, 2021), File No. 001-39446: press release on plans to…
CureVac N.V. Form 6-K (March 23, 2021)CureVac N.V. Form 6-K (March 23, 2021), File No. 001-39446: press release on preclinical…
CureVac N.V. Form 6-K (March 4, 2021)CureVac N.V. Form 6-K (March 4, 2021), File No. 001-39446: press release on an initial…
CureVac N.V. Form 6-K (May 13, 2021)CureVac N.V. Form 6-K (May 13, 2021), File No. 001-39446: press release with GSK on first…
CureVac N.V. Form 6-K (May 26, 2021)CureVac N.V. Form 6-K (May 26, 2021), File No. 001-39446: press release on first-quarter…
CureVac N.V. Form 6-K (May 28, 2021)CureVac N.V. Form 6-K (May 28, 2021), File No. 001-39446: press release saying the HERALD…
CureVac N.V. Form 6-K (Nov. 10, 2020)CureVac N.V. Form 6-K, November 10, 2020: press release on detailed interim Phase 1 data…
CureVac N.V. Form 6-K (Nov. 12, 2020)CureVac N.V. Form 6-K, November 12, 2020: press release on stability of its COVID-19…
CureVac N.V. Form 6-K (Nov. 16, 2020)CureVac N.V. Form 6-K, November 16, 2020: press release on European Commission purchase…
CureVac N.V. Form 6-K (Nov. 17, 2020)CureVac N.V. Form 6-K, November 17, 2020: press release on expansion of its manufacturing…
CureVac N.V. Form 6-K (Nov. 2, 2020)CureVac N.V. Form 6-K, November 2, 2020: press release on interim Phase 1 data for its…
CureVac N.V. Form 6-K (Nov. 30, 2020)CureVac N.V. Form 6-K, November 30, 2020: press release on financial results for the…
CureVac N.V. Form 6-K (Oct. 23, 2020)CureVac N.V. Form 6-K, October 23, 2020: press release on preclinical data for its…
CureVac N.V. Form 6-K (Sept. 29, 2020)CureVac N.V. Form 6-K, September 29, 2020: press release on Phase 2a trial CV-NCOV-002 of…
CureVac N.V. Form 6-K (Sept. 4, 2020)CureVac N.V. Form 6-K, September 4, 2020: press release on BMBF support of up to 252…
CureVac N.V. Form F-1 (Jan. 25, 2021)CureVac N.V. Form F-1 registration statement (SEC, Jan. 25, 2021): 5,000,000 common…
CureVac N.V., Form 20-F (December 31, 2022)Archived source document: CureVac N.V., Form 20-F (December 31, 2022).
CureVac N.V., Form 6-K, For the month of January 2026Archived source document: CureVac N.V., Form 6-K, For the month of January 2026.
CureVac N.V., Form 6-K, For the month of July 2024Archived source document: CureVac N.V., Form 6-K, For the month of July 2024.
Current Opinion in Behavioral Sciences 2017, 18:7–12Current Opinion in Behavioral Sciences 2017, 18:7–12: court filing dated February 6, 2023. Full…
Current Population Survey 2021 ASEC Supplement Technical Documentation — U.S. Census BureauNtiality Protection Sampling Error Nonsampling Error And Definitions Is Available At…
Current State of the Auto Insurance MarketSlides on the current state of the auto insurance market, November 30, 2023: cost drivers…
Current State of the Property Casualty Insurance MarketKaren Collins slides, November 30, 2023, for the Washington Senate Business, Financial…
Current Status of Unemployment Insurance (UI) Benefits: Permanent-Law Programs and COVID-19 Pandemic Response (R46687, Version 1)Archived source document: Current Status of Unemployment Insurance (UI) Benefits:…
Current Status of Unemployment Insurance (UI) Benefits: Permanent-Law Programs and COVID-19 Pandemic Response (R46687, Version 3, Updated March 23, 2021)Current Status of Unemployment Insurance (UI) Benefits: Permanent-Law Programs and…
Current Status of Unemployment Insurance (UI) Benefits: Permanent-Law Programs and COVID-19 Pandemic Response (R46687, Version 5, Updated June 25, 2021)Current Status of Unemployment Insurance (UI) Benefits: Permanent-Law Programs and…
Current Status of Unemployment Insurance (UI) Benefits: Permanent-Law Programs and COVID-19 Pandemic Response (R46687, Version 7, Updated August 22, 2021)Current Status of Unemployment Insurance (UI) Benefits: Permanent-Law Programs and…
Curriculum Vitae of Michael J. Boskin, Stanford University and Hoover InstitutionCurriculum vitae of Stanford economist Michael J. Boskin, with public service, honors and…
Curriculum Vitae — Charles W. Calomiris (June 2023)Curriculum vitae of Charles W. Calomiris, dated June 2023: academic and policy positions,…
Customer: Homebase — Providing faster access to wagesPlaid customer story on Homebase and faster earned wage access through Real-Time…
Customers Bancorp, Inc. Class Action Lawsuit - CUBI (Robbins Geller Rudman & Dowd case page)Robbins Geller page on Chang v. Customers Bancorp, No. 24-cv-06416 (E.D. Pa.): class…
Customers Bancorp, Inc. Form 10-K (Dec. 31, 2019)Customers Bancorp, Inc. Form 10-K for fiscal year 2019: cover data, BankMobile risk…
Customers Bancorp, Inc. Form 10-K (Dec. 31, 2020)Customers Bancorp, Inc. Form 10-K for the fiscal year ended December 31, 2020, signed…
Customers Bancorp, Inc. Form 10-K (Dec. 31, 2021)Customers Bancorp, Inc. Form 10-K for the fiscal year ended December 31, 2021, signed…
Customers Bancorp, Inc. Form 10-Q (June 30, 2020)Customers Bancorp, Inc. Form 10-Q for the quarter ended June 30, 2020: total assets…
Customers Bancorp, Inc. Form 10-Q (June 30, 2021)Customers Bancorp, Inc. Form 10-Q for the quarter ended June 30, 2021: total assets…
Customers Bancorp, Inc. Form 10-Q (June 30, 2022)Customers Bancorp, Inc. Form 10-Q for the quarter ended June 30, 2022: total assets…
Customers Bancorp, Inc. Form 10-Q (March 31, 2020)Customers Bancorp, Inc. Form 10-Q for the quarter ended March 31, 2020: net income $3,100…
Customers Bancorp, Inc. Form 10-Q (March 31, 2021)Customers Bancorp, Inc. Form 10-Q for the quarter ended March 31, 2021: net income…
Customers Bancorp, Inc. Form 10-Q (March 31, 2022)Customers Bancorp, Inc. Form 10-Q for the quarter ended March 31, 2022: net income…
Customers Bancorp, Inc. Form 10-Q (Sept. 30, 2020)Customers Bancorp, Inc. Form 10-Q for the quarter ended September 30, 2020: total assets…
Customers Bancorp, Inc. Form 10-Q (Sept. 30, 2021)Customers Bancorp, Inc. Form 10-Q for the quarter ended September 30, 2021: net income…
Customers Bancorp, Inc. Form 10-Q (Sept. 30, 2022)Customers Bancorp, Inc. Form 10-Q for the quarter ended September 30, 2022: total assets…
Customers Bank, investor-relations biography of Jay Sidhu birth 1951, Punjab; 1971 immigration; Wilkes MBA; Sovereign...Biography of Jay Sidhu, Executive Chairman of Customers Bancorp: Customers Bank since…
Customers Bank, investor-relations biography of Sam Sidhu Wharton BS, Harvard MBA, Goldman, Providence, Megalith; cur...Customers Bank investor-relations biography of Sam Sidhu, Vice Chairman, President and…
Customers-Kabbage Third Declaration of Alyssa White FINAL(183113169.1) - COSCustomers-Kabbage Third Declaration of Alyssa White FINAL(183113169.1) - COS…: congressional…
Cyber Security For Public Services Critical Infrastructure - Best Practices (January 13th 2023)Cyber security best practices for public services critical infrastructure, covering…
Cybersecurity and Critical Infrastructure — House Technology, Economic Development, and Veterans Committee (WaTech, January 30, 2026)Slides on Cybersecurity and Critical Infrastructure for the House Technology, Economic…
Cybersecurity Opportunity Act — Report, Senate, 117th Congress, 2d Session 117–59 (Calendar No. 256)Senate Report 117-59 of January 20, 2022 on S. 2305, the Cybersecurity Opportunity Act,…
Cybersecurity: Challenges and Opportunities for Small BusinessesHearing page of August 15, 2023 in Colorado Springs on cybersecurity for small…
CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 ProgramArchived source document: CytoDyn Announces Partial Clinical Hold of HIV Program and Full…
CYTODYN INC. Form 10-K (May 31, 2020)CytoDyn Inc. Form 10-K for fiscal year ended May 31, 2020 (No. 000-49908), signed August…
CYTODYN INC. Form 10-K (May 31, 2021)CytoDyn Inc. Form 10-K for fiscal year ended May 31, 2021, signed July 30, 2021:…
CYTODYN INC. Form 10-K (May 31, 2022)CytoDyn Inc. Form 10-K for fiscal year ended May 31, 2022, signed August 15, 2022:…
CYTODYN INC. Form 10-Q (Aug. 31, 2020)CytoDyn Inc. Form 10-Q for quarter ended Aug. 31, 2020 (No. 000-49908), October 9, 2020:…
CYTODYN INC. Form 10-Q (Aug. 31, 2021)CytoDyn Inc. Form 10-Q for quarter ended Aug. 31, 2021 (No. 000-49908), October 12, 2021:…
CYTODYN INC. Form 10-Q (Aug. 31, 2022)CytoDyn Inc. Form 10-Q for quarter ended Aug. 31, 2022 (No. 000-49908), October 11, 2022:…
CYTODYN INC. Form 10-Q (Feb. 28, 2021)CytoDyn Inc. Form 10-Q for quarter ended Feb. 28, 2021 (No. 000-49908), April 14, 2021:…
CYTODYN INC. Form 10-Q (Feb. 28, 2022)CytoDyn Inc. Form 10-Q for quarter ended Feb. 28, 2022 (No. 000-49908), April 11, 2022:…
CYTODYN INC. Form 10-Q (Feb. 29, 2020)CytoDyn Inc. Form 10-Q for quarter ended Feb. 29, 2020 (No. 000-49908), April 9, 2020:…
CYTODYN INC. Form 10-Q (Nov. 30, 2019)CytoDyn Inc. Form 10-Q for quarter ended Nov. 30, 2019 (No. 000-49908), January 9, 2020:…
CYTODYN INC. Form 10-Q (Nov. 30, 2020)CytoDyn Inc. Form 10-Q for quarter ended Nov. 30, 2020 (No. 000-49908), January 8, 2021:…
CYTODYN INC. Form 10-Q (Nov. 30, 2021)CytoDyn Inc. Form 10-Q for quarter ended Nov. 30, 2021 (No. 000-49908), January 10, 2022:…
CYTODYN INC. Form 10-Q (Nov. 30, 2022)CytoDyn Inc. Form 10-Q for quarter ended Nov. 30, 2022 (No. 000-49908), January 9, 2023:…
CytoDyn Inc. Form 10-Q for the quarter ended Feb. 28, 2023CytoDyn Inc. Form 10-Q for quarter ended Feb. 28, 2023 (No. 000-49908), April 10, 2023:…
CytoDyn Inc. Form 4 (Aug. 15, 2022) — Migliarese AntonioCytoDyn Inc. Form 4, August 15, 2022: CFO Antonio Migliarese acquired 5,208 common shares…
CytoDyn Inc. Form 4 (Aug. 31, 2022) — Migliarese AntonioCytoDyn Inc. Form 4 (August 31, 2022): CFO Antonio Migliarese acquired 8,313 common…
CytoDyn Inc. Form 4 (July 15, 2022) — Migliarese AntonioCytoDyn Inc. (CYDY) officer Migliarese Antonio: Form 4 for 9,824 fully vested shares…
CytoDyn Inc. Form 4 (July 31, 2022) — Migliarese AntonioCytoDyn Inc. (CYDY) Form 4 for Migliarese Antonio, CFO & Interim President: 5,614 fully…
CytoDyn Inc. Form 4 (June 15, 2022) — Migliarese AntonioForm 4 for CytoDyn Inc. (CYDY) CFO & Interim President Migliarese Antonio: 10,807 fully…
CytoDyn Inc. Form 4 (June 30, 2022) — Migliarese AntonioForm 4 for Migliarese Antonio, CytoDyn Inc. (CYDY): 10,292 fully vested shares on…
CytoDyn Inc. Form 4 (March 31, 2022) — Migliarese AntonioForm 4 for CytoDyn Inc. (CYDY) officer Migliarese Antonio: fully vested shares granted in…
CytoDyn Inc. Form 4 (March 31, 2022) — Recknor Chris PForm 4 for Recknor Chris P, CytoDyn Inc. (CYDY) Sr. VP Clinical Operations until…
CytoDyn Inc. Form 4 (Nov. 24, 2021) — Gardiner Gordon ACytoDyn Inc. (CYDY) director Gardiner Gordon A: Form 4 on a $1.39 option amended when…
CytoDyn Inc. Form 4 (Nov. 24, 2021) — Patel Samir RashmikantForm 4 for Patel Samir Rashmikant, CytoDyn Inc. (CYDY) director: $1.39, $6.15 and $2.25…
CytoDyn Inc. Form 4 (Nov. 24, 2021) — TIMMINS ALAN PForm 4 for CytoDyn Inc. (CYDY) director TIMMINS ALAN P: options amended when board…
CytoDyn Inc. Form 4 (Oct. 18, 2021) — Gardiner Gordon ACytoDyn Inc. (CYDY) Form 4 for director Gardiner Gordon A: 225,000-share option at $1.39,…
CytoDyn Inc. Form 4 (Oct. 18, 2021) — Naydenov Jordan GForm 4 for CytoDyn Inc. (CYDY) director Naydenov Jordan G: option for 225,000 shares at…
CytoDyn Inc. Form 4 (Oct. 18, 2021) — Patel Samir RashmikantPatel Samir Rashmikant, CytoDyn Inc. (CYDY) director, Form 4: non-qualified option on…
CytoDyn Inc. Form 4 (Oct. 18, 2021) — Pourhassan NaderForm 4 for Pourhassan Nader, CytoDyn Inc. (CYDY) President & CEO: option on 4,275,000…
CytoDyn Inc. Form 4 (Oct. 18, 2021) — TIMMINS ALAN PCytoDyn Inc. (CYDY) director TIMMINS ALAN P: Form 4 reporting a 225,000-share…
CytoDyn Inc. Form 4 (Sept. 15, 2022) — Migliarese AntonioCytoDyn Inc. Form 4 (September 15, 2022): CFO Antonio Migliarese acquired 7,086 common…
CytoDyn Inc. Form 4 (Sept. 20, 2022) — Arman Arvin CyrusCytoDyn Inc. Form 4, September 20, 2022: Arman Arvin Cyrus (President) received 646,552…
CytoDyn Inc. Form 4 (Sept. 20, 2022) — Migliarese AntonioCytoDyn Inc. Form 4, September 20, 2022: CFO Antonio Migliarese received 630,222 stock…
CytoDyn Inc. Form 4 (Sept. 6, 2022) — Brunke Karen JCytoDyn Inc. Form 4, September 6, 2022: director Brunke Karen J received options on…
CytoDyn Inc. Form 4 (Sept. 6, 2022) — Dunlap RyanCytoDyn Inc. Form 4, September 6, 2022: director Dunlap Ryan received 185,333 stock…
CytoDyn Inc. Form 4 (Sept. 6, 2022) — Ndhlovu Lishomwa CCytoDyn Inc. Form 4: director Ndhlovu Lishomwa C acquired stock options of 112,500,…
CytoDyn Inc. Form 4 (Sept. 6, 2022) — Urbach Tanya DurkeeCytoDyn Inc. Form 4, September 6, 2022: director Urbach Tanya Durkee received stock…
CytoDyn Inc. Form 4 — Arman Arvin Cyrus (Feb. 13, 2023)CytoDyn Inc. Form 4, February 13, 2023: Arman Arvin Cyrus (President) bought 434,782…
CytoDyn Inc. Form 4 — Kelly Scott A. (Nov. 15, 2022)CytoDyn Inc. Form 4 (November 15, 2022): CMO Kelly Scott A. acquired 15,234 common…
CytoDyn Inc. Form 4 — Kelly Scott A. (Nov. 28, 2022)CytoDyn Inc. Form 4: Kelly Scott A. (CMO) received 2,315,439 stock options at $0.35 on…
CytoDyn Inc. Form 4 — Kelly Scott A. (Oct. 15, 2022)CytoDyn Inc. Form 4, October 15, 2022: Kelly Scott A. (CMO) acquired 13,849 common…
CytoDyn Inc. Form 4 — Kelly Scott A. (Oct. 31, 2022)CytoDyn Inc. Form 4: Kelly Scott A. (CMO) acquired 17,922 common shares on October 31,…
CytoDyn Inc. Form 4 — Kelly Scott A. (Sept. 30, 2022)CytoDyn Inc. Form 4: Kelly Scott A. (director, CMO) acquired 18,793 common shares on…
CytoDyn Inc. Form 4 — Migliarese Antonio (Nov. 15, 2022)CytoDyn Inc. Form 4, November 15, 2022: CFO Antonio Migliarese acquired 10,807 common…
CytoDyn Inc. Form 4 — Migliarese Antonio (Nov. 28, 2022)CytoDyn Inc. Form 4: CFO Antonio Migliarese received 4,585,536 stock options at $0.35 on…
CytoDyn Inc. Form 4 — Migliarese Antonio (Oct. 15, 2022)CytoDyn Inc. Form 4, October 15, 2022: CFO Antonio Migliarese acquired 9,824 common…
CytoDyn Inc. Form 4 — Migliarese Antonio (Oct. 31, 2022)CytoDyn Inc. Form 4, October 31, 2022: Antonio Migliarese (CFO) acquired 12,714 common…
CytoDyn Inc. Form 4 — Migliarese Antonio (Sept. 30, 2022)CytoDyn Inc. Form 4 (September 30, 2022): CFO Antonio Migliarese acquired 10,292 common…
CytoDyn Inc. Form 4 — Ray Nitya G. (Nov. 15, 2022)CytoDyn Inc. Form 4, November 15, 2022: Chief Technology Officer Ray Nitya G. acquired…
CytoDyn Inc. Form 4 — Ray Nitya G. (Oct. 15, 2022)CytoDyn Inc. Form 4: Ray Nitya G. (Chief Technology Officer) acquired 12,428 common…
CytoDyn Inc. Form 4 — Ray Nitya G. (Oct. 31, 2022)CytoDyn Inc. Form 4 (October 31, 2022): Chief Technology Officer Ray Nitya G. acquired…
CytoDyn Inc. Form 4 — Ray Nitya G. (Sept. 30, 2022)CytoDyn Inc. Form 4, September 30, 2022: Ray Nitya G. (Chief Technology Officer) acquired…
CytoDyn Inc. Form 4 — SIMES STEPHEN M (Oct. 24, 2022)CytoDyn Inc. Form 4, October 24, 2022: director SIMES STEPHEN M received 178,012 stock…
CytoDyn Inc. Form 8-K (April 12, 2021)CytoDyn Inc. Form 8-K (April 12, 2021): exclusive supply and distribution agreement with…
CytoDyn Inc. Form 8-K (April 17, 2020)CytoDyn Inc. Form 8-K (event April 17, 2020): board appoints Samir R. Patel, M.D. as a…
CytoDyn Inc. Form 8-K (April 19, 2022)CytoDyn Inc. Form 8-K (April 19, 2022): Item 4.01 Warren Averett resigns as auditor;…
CytoDyn Inc. Form 8-K (April 21, 2021)CytoDyn Inc. Form 8-K (April 21, 2021): exclusive distribution agreement with Chiral…
CytoDyn Inc. Form 8-K (April 23, 2020)CytoDyn Inc. Form 8-K (April 23, 2020): Michael D. Mulholland appointed Interim Chief…
CytoDyn Inc. Form 8-K (April 24, 2020)CytoDyn Inc. Form 8-K (April 24, 2020): derivative stockholder complaint in Delaware…
CytoDyn Inc. Form 8-K (April 25, 2022)CytoDyn Inc. Form 8-K, April 25, 2022: Nitya G. Ray no longer chief operating officer;…